StreetInsider.com News Articles

Form 4 PALISADE BIO, INC. For: Jun 10 Filed by: Baltera Robert Jr.

Thu, 18 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260618/26666070.html

Form 4 PALISADE BIO, INC. For: Jun 10 Filed by: Baltera Robert Jr.

Thu, 18 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260618/26666070.html

Form 3 PALISADE BIO, INC. For: Jun 10 Filed by: Baltera Robert Jr.

Thu, 18 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260618/26665914.html

Form 3 PALISADE BIO, INC. For: Jun 10 Filed by: Baltera Robert Jr.

Thu, 18 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260618/26665914.html

Form 4 PALISADE BIO, INC. For: Jun 10 Filed by: Wei Binxian

Fri, 12 Jun 2026 20:14:00 -0400

si-local-file:///var/storage/secattach/20260612/26642578.html

Form 4 PALISADE BIO, INC. For: Jun 10 Filed by: Wei Binxian

Fri, 12 Jun 2026 20:14:00 -0400

si-local-file:///var/storage/secattach/20260612/26642578.html

Form 4 PALISADE BIO, INC. For: Jun 10 Filed by: Williams Donald Allen

Fri, 12 Jun 2026 20:12:00 -0400

si-local-file:///var/storage/secattach/20260612/26642575.html

Form 4 PALISADE BIO, INC. For: Jun 10 Filed by: Williams Donald Allen

Fri, 12 Jun 2026 20:12:00 -0400

si-local-file:///var/storage/secattach/20260612/26642575.html

Form 4 PALISADE BIO, INC. For: Jun 10 Filed by: Chuang Emil

Fri, 12 Jun 2026 20:11:00 -0400

si-local-file:///var/storage/secattach/20260612/26642573.html

Form 4 PALISADE BIO, INC. For: Jun 10 Filed by: Chuang Emil

Fri, 12 Jun 2026 20:11:00 -0400

si-local-file:///var/storage/secattach/20260612/26642573.html

Form 4 PALISADE BIO, INC. For: Jun 10 Filed by: Zwick Jordan Michael

Fri, 12 Jun 2026 20:09:00 -0400

si-local-file:///var/storage/secattach/20260612/26642566.html

Form 4 PALISADE BIO, INC. For: Jun 10 Filed by: Zwick Jordan Michael

Fri, 12 Jun 2026 20:09:00 -0400

si-local-file:///var/storage/secattach/20260612/26642566.html

Form 3 PALISADE BIO, INC. For: Jun 10 Filed by: Zwick Jordan Michael

Fri, 12 Jun 2026 20:08:00 -0400

si-local-file:///var/storage/secattach/20260612/26642562.html

Form 3 PALISADE BIO, INC. For: Jun 10 Filed by: Zwick Jordan Michael

Fri, 12 Jun 2026 20:08:00 -0400

si-local-file:///var/storage/secattach/20260612/26642562.html

Form 8-K PALISADE BIO, INC. For: Jun 10

Thu, 11 Jun 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260611/26636861.html

Form 8-K PALISADE BIO, INC. For: Jun 10

Thu, 11 Jun 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260611/26636861.html

Palisade Bio adds two industry veterans to board of directors

Thu, 11 Jun 2026 08:45:13 -0400

Palisade Bio Inc. (NASDAQ: PALI) announced the appointment of Robert Baltera and Jordan Zwick to its board of directors. The clinical-stage biopharmaceutical company develops oral PDE4 inhibitor prodrugs for inflammatory bowel diseases.

Baltera brings over 30 years of biopharmaceutical experience, having served as CEO of Cirius Therapeutics and Amira Pharmaceuticals. During his tenure at Amira, the company was sold to Bristol-Myers Squibb for $475 million in 2011. He previously held senior management positions at Amgen for 17 years and currently serves as a senior advisor at Frazier Life Sciences.

Zwick co-founded Mirador Therapeutics and serves as its chief business officer. He advised

Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors

Thu, 11 Jun 2026 08:45:00 -0400

Board strengthened with extensive biotechnology leadership, strategic transactions and capital markets expertise

Company continues to build on PALI-2108 clinical progress as it advances toward Phase 2 development and additional key milestones

Denver, CO, June 11, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced the addition of Robert Baltera and Jordan Zwick to its Board of Directors.

“We are pleased to welcome both Robert

Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors

Thu, 11 Jun 2026 08:45:00 -0400

Board strengthened with extensive biotechnology leadership, strategic transactions and capital markets expertise

Company continues to build on PALI-2108 clinical progress as it advances toward Phase 2 development and additional key milestones

“We are pleased to welcome both Robert

Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors

Thu, 11 Jun 2026 08:45:00 -0400

Board strengthened with extensive biotechnology leadership, strategic transactions and capital markets expertise

Company continues to build on PALI-2108 clinical progress as it advances toward Phase 2 development and additional key milestones

“We are pleased to welcome both Robert

Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors

Thu, 11 Jun 2026 08:45:00 -0400

Board strengthened with extensive biotechnology leadership, strategic transactions and capital markets expertise

Company continues to build on PALI-2108 clinical progress as it advances toward Phase 2 development and additional key milestones

“We are pleased to welcome both Robert

Form S-8 PALISADE BIO, INC.

Wed, 10 Jun 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260610/26630577.html

Form S-8 PALISADE BIO, INC.

Wed, 10 Jun 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260610/26630577.html

Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium

Tue, 09 Jun 2026 08:45:00 -0400

Presentation to highlight fibrostenotic Crohn’s disease biology and the potential of a locally bioactivated PDE4 inhibitor prodrug approach

Denver, CO, June 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced Mitchell Jones, MD, PhD, President and Chief Medical Officer, will present at the New York Academy of Sciences (“NYAS”) symposium, Molecular Pathways and Cellular Players in the Resolution of Organ Fibrosis, taking place on June 9, 2026,

Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium

Tue, 09 Jun 2026 08:45:00 -0400

Presentation to highlight fibrostenotic Crohn’s disease biology and the potential of a locally bioactivated PDE4 inhibitor prodrug approach